{
    "root": "b34d3b22-bb47-428e-941e-3be596a2e9de",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Deflazacort",
    "value": "20240806",
    "ingredients": [
        {
            "name": "DEFLAZACORT",
            "code": "KR5YZ6AE4B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135720"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        }
    ],
    "indications": {
        "text": "deflazacort tablets indicated treatment duchenne muscular dystrophy ( dmd ) patients 5 years age older . additional pediatric information approved ptc therapeutics , inc. 's emflazatm ( deflazacort ) tablets . however , due ptc therapeutics , inc. 's marketing exclusivity rights , product labeled information .",
        "doid_entities": [
            {
                "text": "duchenne muscular dystrophy (DOID:11723)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11723"
            },
            {
                "text": "muscular dystrophy (DOID:9884)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9884"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended once-daily approximately 0.9 mg/kg/day administered orally ( 2.2 ) discontinue gradually administered days ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "deflazacort tablets contraindicated patients known hypersensitivity deflazacort inactive ingredients . instances hypersensitivity , including anaphylaxis , occurred patients receiving corticosteroid therapy [ ( 5.15 ) ( 6.2 ) ] .",
    "indications_original": "Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.\n                     Additional pediatric use information is approved for PTC Therapeutics, Inc.'s EmflazaTM (deflazacort) tablets. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally (2.2) Discontinue gradually when administered for more than a few days (2.3)",
    "adverseReactions_original": "Deflazacort tablets are contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy [see Warnings and Precautions (5.15) and Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Deflazacort",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135720"
        }
    ]
}